Published in Future Med Chem on September 01, 2014
Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease. Cell Chem Biol (2016) 0.92
Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? Med Res Rev (2015) 0.84
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold. J Med Chem (2016) 0.75
Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy. Curr Diab Rep (2016) 0.75
Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors. Chemistry (2016) 0.75
A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library. Medchemcomm (2017) 0.75
EB1 protein alteration characterizes sporadic but not ulcerative colitis associated colorectal cancer. Oncotarget (2017) 0.75
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A (1994) 6.74
Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell (1997) 6.12
The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol (2001) 6.10
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 6.00
Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell (1998) 5.52
Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell (2005) 4.95
Mitochondria and cancer. Nat Rev Cancer (2012) 4.81
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J (1998) 4.46
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem (1999) 4.02
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther (1998) 3.66
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A (2002) 3.54
CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep (2001) 3.19
The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem (1997) 3.16
Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci U S A (1997) 3.04
Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem (1996) 3.00
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A (1996) 2.90
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem (2000) 2.62
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell (2009) 2.50
The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem (1993) 2.42
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res (2003) 2.27
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta (2011) 2.21
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst (2000) 2.09
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 2.06
Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem (1997) 1.94
The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochim Biophys Acta (2011) 1.90
Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol (2013) 1.84
Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem (2005) 1.81
Structure, function and regulation of the hsp90 machinery. Biomed J (2013) 1.81
Hsp90 and Cdc37 -- a chaperone cancer conspiracy. Curr Opin Genet Dev (2005) 1.78
S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci U S A (2005) 1.77
HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol (1998) 1.76
Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol Endocrinol (1998) 1.76
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc (2006) 1.75
The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J Mol Biol (2005) 1.74
Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc (2005) 1.71
Modification of heat shock protein 90 by 4-hydroxynonenal in a rat model of chronic alcoholic liver disease. J Pharmacol Exp Ther (2005) 1.71
Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J (2002) 1.65
Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J Biol Chem (2008) 1.64
Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem (2008) 1.63
The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine residues. J Biol Chem (1989) 1.60
Structure and functional relationships of Hsp90. Curr Cancer Drug Targets (2003) 1.59
Heat shock protein 90: inhibitors in clinical trials. J Med Chem (2010) 1.57
Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta (2011) 1.56
Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J Biol Chem (1989) 1.56
The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets (2003) 1.52
Milk thistle in liver diseases: past, present, future. Phytother Res (2010) 1.51
The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem (2008) 1.49
The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A (2009) 1.48
Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem (2009) 1.45
KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol (2009) 1.43
The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci (2013) 1.41
Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry (2004) 1.38
Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem (2011) 1.36
Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl (2009) 1.34
A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem (2001) 1.34
HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov (2014) 1.32
Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol (2008) 1.32
HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem (2009) 1.26
Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J Biol Chem (2003) 1.25
Hsp90: a drug target? Curr Oncol Rep (2010) 1.24
Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep (2009) 1.24
Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res (2001) 1.22
A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J Biol Chem (2002) 1.22
Functional dissection of cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry (2003) 1.21
Hsp90 as a target for drug development. ChemMedChem (2006) 1.20
Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol (2011) 1.19
Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site. Eur J Biochem (2003) 1.19
Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. Mol Cell (2014) 1.19
Geldanamycin restores a defective heat shock response in vivo. J Biol Chem (2001) 1.19
Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem (2007) 1.18
Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell (2007) 1.18
Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem (2002) 1.17
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer (2011) 1.17
Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. Biochemistry (2010) 1.17
Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proc Natl Acad Sci U S A (2010) 1.17
Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol (2013) 1.16
Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life (1999) 1.15
p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry (2000) 1.13
Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Chem (2005) 1.13
Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. Biochemistry (1999) 1.13
The 'active life' of Hsp90 complexes. Biochim Biophys Acta (2011) 1.13
Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci (2009) 1.12
Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem (2009) 1.11
Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry (2005) 1.10
HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta (2011) 1.08
Structural basis for assembly of Hsp90-Sgt1-CHORD protein complexes: implications for chaperoning of NLR innate immunity receptors. Mol Cell (2010) 1.07
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J Biol Chem (2013) 1.07
Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat Struct Mol Biol (2013) 1.06
(-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry (2009) 1.06
Development of a Grp94 inhibitor. J Am Chem Soc (2012) 1.06
The Pih1-Tah1 cochaperone complex inhibits Hsp90 molecular chaperone ATPase activity. J Biol Chem (2010) 1.05
Intramolecular Diels-Alder and tandem intramolecular Diels-Alder/1,3-dipolar cycloaddition reactions of 1,3,4-oxadiazoles. J Am Chem Soc (2002) 2.18
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc (2006) 1.75
Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc (2005) 1.71
Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem (2008) 1.63
Intramolecular diels-alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles. J Am Chem Soc (2006) 1.63
A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem Biol (2006) 1.62
Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol (2012) 1.59
Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets (2007) 1.51
The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem (2008) 1.49
KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol (2009) 1.43
Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem (2011) 1.36
Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org Lett (2006) 1.33
E. coli MEP synthase: steady-state kinetic analysis and substrate binding. Biochemistry (2002) 1.32
To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem (2009) 1.29
A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett (2007) 1.27
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro (2010) 1.21
Hsp90 as a target for drug development. ChemMedChem (2006) 1.20
Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol (2011) 1.19
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer (2011) 1.17
Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biol Reprod (2008) 1.13
Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays. Comb Chem High Throughput Screen (2013) 1.12
High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorg Med Chem (2007) 1.11
Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity. ACS Med Chem Lett (2010) 1.10
Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett (2005) 1.09
Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org Lett (2004) 1.08
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J Biol Chem (2013) 1.07
Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J Mol Biol (2009) 1.06
Development of a Grp94 inhibitor. J Am Chem Soc (2012) 1.06
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorg Med Chem (2008) 1.05
A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem (2010) 1.04
Hsp90 modulation for the treatment of Alzheimer's disease. Adv Pharmacol (2012) 1.03
Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem (2006) 1.03
Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90. J Org Chem (2006) 1.03
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem (2009) 1.02
Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg Med Chem Lett (2010) 1.02
High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett (2006) 1.02
A library of noviosylated coumarin analogues. J Org Chem (2007) 1.01
3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett (2012) 1.01
Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification. Mol Pharm (2010) 1.00
Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorg Med Chem (2005) 0.99
Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorg Med Chem (2008) 0.96
Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate (2010) 0.96
C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. J Proteome Res (2012) 0.96
Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod (2011) 0.96
Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg Med Chem Lett (2006) 0.95
Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. J Biol Chem (2012) 0.95
Hsp90 inhibition: elimination of shock and stress. Bioorg Med Chem Lett (2010) 0.95
Synthesis and evaluation of electron-rich curcumin analogues. Bioorg Med Chem (2008) 0.94
Syntheses of photolabile novobiocin analogues. Bioorg Med Chem Lett (2004) 0.94
Biotinylated geldanamycin. J Org Chem (2004) 0.92
Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. J Med Chem (2012) 0.92
Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J Org Chem (2013) 0.91
Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem (2011) 0.91
A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. Assay Drug Dev Technol (2010) 0.90
Synthesis and evaluation of derrubone and select analogues. J Org Chem (2007) 0.89
The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Mol Pharm (2012) 0.89
Derrubone, an inhibitor of the Hsp90 protein folding machinery. J Nat Prod (2007) 0.88
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Synthesis of mono- and dihydroxylated furanoses, pyranoses, and an oxepanose for the preparation of natural product analogue libraries. J Org Chem (2005) 0.86
Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues. Bioorg Med Chem Lett (2010) 0.86
3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. ACS Med Chem Lett (2012) 0.86
Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem (2012) 0.86
Novobiocin analogues with second-generation noviose surrogates. Bioorg Med Chem Lett (2012) 0.85
Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett (2009) 0.84
Synthesis of (-)-noviose from 2,3-O-isopropylidene-D-erythronolactol. J Org Chem (2004) 0.84
Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol (2014) 0.83
Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. J Org Chem (2009) 0.83
Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett (2011) 0.83
Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Ann Surg Oncol (2011) 0.82
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro (2012) 0.81
Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model (2014) 0.81
Synthesis of cruentaren A. Org Lett (2012) 0.79
The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone. Bioorg Med Chem (2009) 0.79
Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol (2013) 0.78
Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells. Bioorg Med Chem Lett (2007) 0.78
KU-32, a novel drug for diabetic neuropathy, is safe for human islets and improves in vitro insulin secretion and viability. Exp Diabetes Res (2012) 0.78
Hydrating for resistance to radicicol. ACS Chem Biol (2009) 0.77
Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorg Med Chem Lett (2009) 0.77
Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery. ACS Chem Biol (2014) 0.76
Heat shock response and insulin-associated neurodegeneration. Trends Pharmacol Sci (2011) 0.75
Synthesis of a versatile metacyclophane macrolactam. Tetrahedron Lett (2008) 0.75
Monoenomycin: A Simplified Trienomycin A Analogue that Manifests Anticancer Activity. ACS Med Chem Lett (2011) 0.75
A versatile approach toward the ansamycin antibiotics. Org Lett (2006) 0.75
Recent advances in medicinal chemistry. Bioorg Med Chem Lett (2011) 0.75
Inhibition and function of heat shock proteins 70 and 90. Curr Top Med Chem (2009) 0.75